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Metabolic Syndrome (MS) may be characterized with obesity and insulin resistance. In obesity, the increased 
accumulation of fat in the circulation and tissues will lead to Reactive Oxygen Species (ROS), followed by 
oxidative stress. Nonalcoholic Fatty Liver Disease (NAFLD), the accumulation of excess free fat in the form 
of triglycerides caused by lipolysis due to insulin resistance, can cause inflammation and liver cells damage 
characterized by increased serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic 
transaminase (SGPT). Nigella Sativa (Black Seed) oil is known to be efficacious as an antioxidant that can 
improve hepatic function. This study uses a cross over design to determine the effect of black seed oil with a 
dose of 1.5 ml/day and 3 ml/day on SGOT and SGPT activities in patients with SM. A total of 62 SM patients 
were divided into two groups which received 1.5 ml/day and 3 ml/day respectively for 20 days, and after 7-
day washout, the doses were reversed. Measurements were performed on the 21st and 49th days. The results 
showed a significant difference in SGOT activity decrease in patients receiving 1.5 ml/day compared with 
those receiving 3 ml/day. However, in terms of SGPT, there was no significant difference between the two 
treatment groups. 
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1. INTRODUCTIO
N 
Metabolic syndrome (MS) is a metabolic 
disorder in the body caused by risk factors such as 
obesity, dyslipidemia, hypertension, or insulin resistance 
(Matsuzawa, 2010). SM in Indonesia is one of the major 
public health issues. SM incidence rate in Indonesia 
reached 23%, with 26.6% in women and 18.3% in men 
of productive age based on Basic Health Research (Riset 
Kesehatan Dasar, or RISKESDAS) (Kemenkes RI, 
2013). SM is closely associated with regenerative 
diseases incidence, one of which is Nonalcoholic Fatty 
Liver Disease (NAFLD). Approximately 90% of 
NAFLD patients meets one of MS criteria and 
approximately 33% meets three or more of the criteria 
(Marzio et al., 2014). Research conducted by Nadila et 
al., in 2015 mentions that of 30 MS patients who came 
for treatment in Internal Medicine Clinic of Dr. M. Jamil 
General Hospital in Padang, 20 patients (67%) were 
diagnosed with NAFLD. 
According to the World Gastroenterology 
Organization (WGO) in 2012, fatty liver disease (FLD) 
is a condition in which excess fat accumulation in the 
form of triglycerides affects 5% of hepatocytes in the 
liver. In some FLD patients, hepatocyte cell damage was 
detected with an inflammatory response to fatty deposits 
in the liver (Nadya, 2015). The presence of excessive fat 
accumulation in the liver will cause fatty liver which 
then causes inflammation and damage to hepatic cells. 
This is caused by the accumulation of fat, or obesity, in 
liver cells and insulin resistance. In the latter case, 
adipose tissue is no longer able to cope with excess fat 
levels, causing lipolysis that produces free fatty acid 
(FFA) in excess amount, which will be transported by 
the portal vein to the liver. The accumulation in the liver 
will lead to mitochondrial dysfunction, increased 
proinflammatory cytokines, oxidative stress leading to 
increased liver cell sensitivity to injury, and liver cells 
inflammation and necrosis (Lesmana, 2009). As many as 
15-50% of FLD cases will develop into fibrosis and 25% 
progress to nonalcoholic steatohepatitis (NASH) with 
10% mortality rate (Sears, 2012). Damage to liver cells 
in NAFLD can be seen from the increased levels of 
SGOT and SGPT, where the higher the increase in 
transaminase or aminotransferase enzymes, the more 
severe the damage level of liver cells (Cahyono, 2009). 
The provision of additional therapy (adjuvant 
therapy) in addition to standard therapy is expected to 
reduce hepatic damage due to dyslipidemia which 
commonly occurs in patients with metabolic syndrome. 
Black seed oil, which contains thymoquinone, has been 
shown to have antioxidant activity and anti-dyslipidemia 
in vivo, and has been proven safe in healthy volunteers 
(Akrom, 2016; Najma et al., 2001). Akrom (2013) states 
that the provision of black seed oil has been proven to 
increase glutathione S-transferase (GST) anti-oxidative 
enzyme and the number of Treg in Sprague Dawley rats 
induced with Dimethylbenzathrene (DMBA) so as to 
inhibit the inflammatory reaction that is excessive and 
remain safe for liver or kidney function. The effect of 
black seed oil adjuvant therapy on SGOT and SGPT 
activities in patients with metabolic syndrome with 
standard therapy is not yet known, and therefore this 
study is aimed at identifying the effect. 
 
2. EXPERIMENTAL DETAILS 
The study uses cross over design with a total of 66 
patients with metabolic syndrome. However, during the 
course of the study, four patients were excluded because 
they experienced side effects such as nausea, vomiting, 
gastritis, increased blood pressure and decreased renal 
function. This research was conducted at Puskesmas Jetis 
I of Bantul Regency, Yogyakarta from August 2016 until 
March 2017. This clinical trial protocol has been 
reviewed and validated by health research ethics 
committee of Medical Faculty, Universitas 
Muhammadiyah Yogyakarta. 
Prospective subjects who meet the inclusion criteria 
were gathered together to receive explanation of the 
research objectives and benefits for the public and 
volunteers. Those who were willing to participate in the 
research then received a further explanation of the 
consequences as volunteers and rewards to be gained. 
Prospective subjects who were voluntarily and consciously 
willing to become research subjects were then asked to fill 
out an informed consent. The subjects who have met the 
selection requirements and filled the informed consent then, 
in a simple randomization, were divided into two treatment 
groups, with each group consisting of 31 volunteers. The 
randomization result codes were kept by the officer. 
Black seed oil is packaged in soft capsule, each 
containing 0.5 ml. In phase I, the treatment group I 
received 1.5 ml/day (1 × 3 soft capsule) dose while the 
treatment group II received 3 ml/day (2 x 3 soft capsule) for 
20 days. On the 12th day, blood sampling was performed to 
examine the SGOT and SGPT activities. After a 7-day 
wash out, on the 28th day, phase II started with the doses 
given in reverse, where the treatment group I received 3 
ml/day while the treatment group II received 1.5 ml/day for 
the next 20 days. SGOT and SGPT levels in phase II were 
measured on the 49th day. 
Demographic data, disease diagnosis, medical history, 
and duration of illness were obtained from medical records 
completed with interviews guided by questionnaires 
conducted by trained personnel. SGOT and SGPT activity 
was measured with spectrophotometer method. 2 ml of 
blood was taken by trained health analysts from the median 
cubital vein using the protocol that has been reviewed and 
approved by health research ethics committee of Medical 
Faculty, Universitas Muhammadiyah Yogyakarta. The 
analysis was conducted at Puskesmas Jetis I, Bantul which 
also serves as the research site. 
Data on subject demographic and clinical characteristics 
are presented descriptively. SGOT and SGPT activity data 
were obtained by inter-group average test on one take with 
one-way ANOVA or unpaired T-test. The difference of 
SGOT and SGPT activity in one group between 
measurements (blood taking) was calculated by paired T-
test. All tests were performed with a 95% significance 
level. 
 
3. RESULTS  AND DISCUSSION 
Demographic and clinical characteristics 
The characteristics of the study subjects are shown in Table 1 
including sex, age, marital status, education, and employment. It 
can be seen that by sex, women tend to suffer more from 
metabolic syndrome than men, with 26 compared to 7 patients in 
each treatment group. By age, 56-64 years are more likely to 
suffer from metabolic syndrome compared with younger age 
groups and the oldest age group (>64 years). This is in line with 
research conducted by Nathania et al., 2015 stating that FLD in 
patients with hypertension (one of the metabolic syndrome 
characteristics) is mostly suffered by women aged 51-60 years. 
Based on education, subjects with low levels of education- from 
non-schoolers to primary school- were more likely to develop 
metabolic syndrome with 33 patients, while subjects with junior-
high school education were 24 patients, and subjects with a 
Diploma and Bachelor degree were 9 patients. Based on 
occupation, 16 patients were those who were unemployed while 
those who work as civil servants accounted for the lowest with 3 
patients. This is in line with research conducted by Krisnawati et 
al., 2012 suggesting that the prevalence of metabolic syndrome in 
women is higher than that in men, but both men and women have 
the same potential for developing metabolic syndrome. It is also 
said that metabolic syndrome risk corresponds to increasing age, 
because organs ability to function has been increasingly 
weakened, including damage to the pancreas in producing insulin 
that triggers other characteristics of metabolic syndrome. 
Similarly, education levels and occupations are also associated 
with metabolic syndrome risk. These data indicate that the 
treatment group I and II have significance values of p>0.05, 
which means that there is no significant difference in the 
characteristics between the two groups.
 
 
Table I. Demographic Characteristics of Research Subjects 
Patient characteristics Group P 
Treatment I 
(N = 33) 
Treatment II 
(N = 33) 
Gender 
Man 
Women 
 
7 (21.2%) 
26 (78.8%) 
 
7 (21.2%) 
26 (78.8%) 
0.618 
Age 
36-45 years old 
46-55 years old 
56-65 years 
> 65 years old 
 
5 (15.2%) 
12 (36.4%) 
13 (39.4%) 
3 (9,1) 
 
4 (12.1%) 
11 (33.3%) 
14 (42.4%) 
4 (12.1%) 
.953 
Marital status 
Married 
Single 
 
32 (97.0%) 
1 (3.0%) 
 
33 (100%) 
0 (0%) 
0.314 
Education 
No school-primary school 
Junior-senior high school 
Diploma-Master 
 
17 (51.5%) 
14 (42.4%) 
2 (6.1%) 
 
16 (48.5%) 
10 (30.3%) 
7 (21.2%) 
0.176 
Occupation 
Civil servants 
Entrepreneur 
Farmers 
Private sector 
Labor 
Fisherman 
Unemployed 
Others 
 
0 (0%) 
3 (9.1%) 
3 (9.1%) 
2 (6.1%) 
7 (21.2%) 
0 (0%) 
11 (33.3%) 
7 (21.2%) 
 
3 (9.1%) 
5 (15.2%) 
5 (15.2%) 
2 (6.1%) 
4 (12.1% 
4 (12.1%) 
5 (15.2%) 
5 (15.2%) 
0.122 
 
 
The characteristics of the metabolic syndrome patients are 
shown in Table II based on metabolic syndrome description, 
illness duration, and drug routinely taken by the patients. A 
person is diagnosed with metabolic syndrome disease when 
they show 2 out of 4 MS criteria according to National 
Cholesterol Education Program (NCEP III). Of the 66 total 
study subjects, the highest numbers were patients with 
diabetes mellitus and hypertension with 16 patients divided 
into two treatment groups. Subjects consume routine drugs 
based on their MS risk and they also routinely check their 
condition in the Puskesmas. Illness duration from MS in this 
research subjects is 1-3 years. The table also shows the 
significance values of p>0.05, which means that there is no 
significant difference in the characteristics between the two 
groups. 
 
Table II. Clinical Characteristics of Metabolic Syndrome Outpatient in Jetis Public Health Center (PHC), Bantul 
MS Characteristics Group P 
Treatment I 
(N = 33) 
Treatment II 
(N = 33) 
Description SM 
DM + Hypertension 
DM + Hypertension + Hypertriglyceridemia 
DM 
DM + Hypercholesterolemia 
Hypertension 
DM + Hypertension + Hypercholesterol 
DM + Hypertension + Obesity 
DM + Hypertension + Hypertriglycerides + 
        Obesity 
DM + Obesity 
DM + Hypertriglycerides 
DM + Hypertension + Hiperdislipidemia 
DM + Hiperdislipidemia 
Hypertriglyceride 
 
8 (24.2%) 
 
4 (12.1%) 
5 (15.2%) 
1 (3.0%) 
1 (3.0%) 
 
3 (9.1%) 
2 (6.1%) 
 
 
0 (0%) 
0 (0%) 
3 (9.1%) 
 
3 (9.1%) 
2 (6.1%) 
1 (3.0%) 
 
8 (24.2%) 
 
8 (24.2%) 
5 (15.2%) 
1 (3.0%) 
0 (0%) 
 
2 (6.1%) 
0 (0%) 
 
 
2 (6.1%) 
1 (3.0%) 
3 (9.1%) 
 
2 (6.1%) 
1 (3.0%) 
0 (0%) 
0.697 
Illness Duration 
<1 year 
1-3 years 
> 3-6 years 
> 6-9 years 
> 9 years 
 
8 (24.2%) 
11 (33.3%) 
6 (18.2%) 
2 (6.1%) 
6 (18.2% 
 
5 (15.2%) 
9 (27.3%) 
7 (21.2%) 
5 (15.2%) 
7 (21.2%) 
0.675 
Routine Medication 
1 drug DM + 1 hypertension medication 
2 drugs DM + 1 hypertension medication 
1 drug DM + 2 hypertensive medication 
1 DM + 2 drug dyslipidemia 
1 DM drug 
1 hypertension medication 
1 drug dyslipidemia 
 
 
7 (21.2%) 
 
6 (18.2%) 
 
1 (3.0%) 
1 (3.0%) 
 
 
10 (30.3%) 
 
6 (18.2%) 
 
1 (3.0%) 
0 (0.0%) 
0.652 
2 DM medications 
2 drugs DM + 2 hypertension medication 
1 drug DM + 1 hypertensive drug + 1 drug 
dyslipidemia 
2 drugs DM + 1 drug dyslipidemia 
3 DM medications 
9 (27.3%) 
1 (3.0%) 
1 (3.0%) 
5 (15.2%) 
 
1 (3.0%) 
 
0 (0.0%) 
1 (3.0%) 
0 (0.0%) 
5 (15.2%) 
0 (0.0%) 
0 (0.0%) 
5 (15.2%) 
 
1 (3.0%) 
 
3 (9.1%) 
1 (3.0%) 
1 (3.0%) 
  
 
Before the study subjects were given treatment (day 0), 
SGOT and SGPT levels were measured, and the results are 
shown in Table III.. 
 
Table III. Pre-treatment clinical condition (SGOT and SGPT levels, blood preesure and  BMI) of Metabolic 
Syndrome Risk Patients receiving standard therapy in PHC Jetis 1 
Clinical Condition Average U/L p value 
SGOT ( U/L) Treatment I (n=33) 
Treatment II (n=33) 
23,64±12,10 
22,64± 8,25 
0,696 
SGPT (U/L) 
 
Treatment I (n=33) 
Treatment II (n=33) 
22,09± 11,53 
22,27± 9,56 
0,945 
  
Table IV. SGOT and SGPT Measurement Results on Day 21 and Day 49 of MS Risk Patients receiving standard and 
adjunctive therapy  (1.5 and 3 ml/day for 2x20 days). 
Clinical 
conditions 
 Average  
Day 21 
P 
value 
Average  
Day 49 
P value 
SGOT Treatment I (n=31) 
Treatment II (n=31) 
23,32 (7,21) 
19,32 (5,82) 
0,019 25,87 (12,05) 
20,32 (5,33) 
0,022 
SGPT Treatment I (n=31) 
Treatment II (n=31) 
20,87 (8,045) 
18,45 (6,01) 
0,185 23,61 (15,72) 
21,45 (7,80) 
0,495 
 
 
 
Day 0 measurements show that subjects SGOT and SGPT 
levels were clinically within normal limits and there is no 
statistically significant difference (p> 0.05). The average of 
SGOT level in treatment group I and II were 23,64±12,10 U/L 
and 22,64±8,25 U/L respectively,  while SGPT were 22,09 
±11,53 U/L and 22,27±9,56 U/L respectively. 
 
SGOT and SGPT Levels after Treatment 
The results of SGOT and SGPT measurements in the first 20 
days (conducted on the 21st day) and the second 20 days 
(conducted on the 49th day) are shown in Table IV. 
Data obtained on Day 21 and 49 measurements were 
analyzed with unpaired T-test stand the results are presented in 
Table IV. The table shows that there was a significant 
difference in SGOT activity between treatment group I and 
treatment II both on day 21 and day 49 with significance value 
of P<0,05. Meanwhile, there was no significant difference in 
SGPT activity between treatment groups on either day 21 or 
day 49 with P > 0.05. The SGOT average day 21 in the 
treatment group I was 23 U/L, while the average in the 
treatment group II was 19 U/L. In addition, the SGPT average 
in the treatment group I was 20 U/L, while the average in the 
treatment group II was 19 U/L. This indicates that 3 ml/day 
dose had better SGOT and SGPT activity compared with 1.5 
ml/day within 20 days of administration. In contrast, the 
SGOT average on day 49 showed no difference in effect 
between 3 ml/day and 1.5 ml/day doses. The treatment group I 
has an average value of 26 U/L, while treatment group II has 
an average value of 20 U/L. This is similar to SGPT activity, 
where the treatment group I has an average value of 24 U/L 
while the treatment group II has an average value of 22 U/L. 
The results also illustrate that the SGOT and SGPT 
activity in the treatment group I show no significant difference 
between the baseline (day 0 measurement) and the 
measurements on day 21 and day 49 with significance value of 
p>0.05. However, in the case of SGPT activity in the 
treatment group II, there was a significant difference between 
the baseline and the day 21 measurements (p <0.05), although 
day 49 measurements did not differ from baseline with 
p>0.05. SGOT activity in the treatment group II on day 21 and 
day 49 measurements was not different with the baseline (p> 
0.05). 
Increased SGOT and SGPT as an indicator of liver 
damage can be prevented or corrected with the use of 
antioxidants (winarsih, 2009). In previous research, it is found 
that Nigella Sativa contains thymoquinone, a compound that is 
efficacious as antioxidants. This active compound is the main 
component of black seed oil which can increase anti-oxidative 
enzyme glutathione S-transferase and the number of Treg in 
mice induced with dimethylbenzathrene (DMBA) so as to 
inhibit the inflammatory reaction (Akrom, 2013). In phase I 
clinical trials, it is evident that black seed oil is safe for liver 
function (Oktaviyanti, 2015). 
  
4. CONCLUSIONS 
It can be concluded that, compared to 1.5 ml/day dose, 
the effect of 3 ml/day dose of black seed oil administered 
for 20 days on SGOT activity of metabolic syndrome risk 
patients receiving standard therapy is higher, although 
such effect is not clinically meaningful. In addition, both 
doses do not clinically affect SGPT activity during the 
treatment period. 
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